CMR Surgical: Galaxy Care Becomes First Hospital in the World to Acquire the Versius Surgical Robotic System
16.10.2019 07:00:00 EEST | Business Wire | Press release
CMR Surgical Ltd today announced that Galaxy Care Hospital in Pune, India, has become the first hospital in the world to procure Versius ® , a next-generation surgical robotic system. A range of surgical procedures have already been conducted using Versius® at the world-renowned centre for laparoscopy, including transthoracic, hysterectomies and myomectomies, under the leadership of Dr. Shailesh Puntambekar.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005940/en/
Galaxy Care is a well-established centre of excellence for laparoscopic surgery and the introduction of Versius ® will support the hospital to bring robotic-assisted laparoscopic surgery to more people. Dr Shailesh Puntambekar, Consultant Oncologist, Surgeon and Medical Director of Galaxy Care will lead the team using Versius ® . He is an international pioneer in surgery and renowned for his advanced laparoscopic skills. In addition to this, he is responsible for training laparoscopy to surgeons from all over the world, helping to bring the benefits of minimal access surgery to patients globally.
Dr Puntambekar has led the way in bringing surgical robotics to India, having performed robotic-assisted surgery in India for over a decade and will be responsible for the introduction of Versius ® to Galaxy Care. Versius ® as a next-generation surgical robotic system with its small form factor, versatility and portability has been designed to support surgeons to deliver the benefits of minimal access surgery to patients around the world.
“As an experienced surgeon in robotic assisted surgery I think that there is significant potential for Versius ® to further increase access to laparoscopic surgery for my patients, so it was a natural choice to acquire this system. Versius ® , as a small and cost-effective system is well suited for meeting the high surgical demand in India. We are excited to bring the next-generation surgical robot to India.” said Dr. Shailesh Puntambekar, Medical Director at Galaxy Care Hospital, Pune, India.
“Galaxy Care has become our first customer to acquire and use Versius ® and this is an important milestone in bringing the benefits of minimal access surgery to all. We are pleased to be working with a centre that has some of the best surgeons in the world, meeting a high surgical demand. It is important that we bring Versius ® to market responsibly and we are delighted to be working closely with Galaxy Care on the introduction of Versius ® in the hospital”, said Mark Slack, Chief Medical Officer, CMR Surgical.
The commercial introduction of Versius ® also marks the launch of the world’s first clinical registry for a surgical robotic system. The registry is part of CMR Surgical’s commitment to post-market surveillance as part of the IDEAL framework and a responsible introduction of a medical device. The clinical registry managed by CMR Surgical, working in partnership with customers is recording and monitoring the patient outcomes of all procedures conducted using the Versius ® Surgical Robotic System in order to ensure patient safety. Outcome measures being recorded include: operative time, length of stay, return to hospital within 30 days, and return to operating room within 24 hours.
In addition to the first global commercial deal taking place in India, the Versius® Surgical Robotic System is expected to be introduced in hospitals across Europe later in 2019.
---ENDS---
About the Galaxy Care Hospital, Pune, India
Galaxy Care Hospital located in Pune, India is a specialist centre in laparoscopic and Robotic cancer surgeries. It has the first and only robotic theatre in western and southern India. The hospital is led by Medical Director Dr. Shailesh Puntambekar who has performed a number of internationally acclaimed procedures including India’s first successful womb transplant as well as pioneering laparoscopic radical hysterectomy for early stage cervical cancer, known globally as the Pune technique. Galaxy Care is now associated with the Care Group of Hospitals, with a number of hospitals across India.
About the Clinical Registry
The clinical registry established by CMR Surgical, working in partnership with customers will support post-market surveillance for the Versius ® Surgical Robotic System. The clinical registry will be collecting the following clinical data on procedures conducted using Versius ® : patient demographics, surgical history, date of diagnosis, planned procedure, operative time, estimated blood loss, return to operating theatre within 24 hours, length of stay, return to hospital within 30 days, mortality at 90 days, any complications that may have occurred. All data is anonymised.
About the Versius® Surgical Robotic System
Versius® resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius® can move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times.
Biomimicking the human arm, Versius® allows surgeons the freedom of port placement, but with the benefits of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.
About CMR Surgical Limited
CMR Surgical is a British private limited company developing the next-generation universal robotic system, Versius®, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius® Surgical Robotic System.
The vision behind CMR Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.
Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.
CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.
The Company achieved the registration of its Quality Management System to ISO 13485:2016 by Underwriters Laboratories LLC® (UL), and the status as a UL Registered Firm, in September 2015.
For further information, please visit www.cmrsurgical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005940/en/
Contact information
CMR Surgical
Patrick Pordage/ Sarah Ghabina
patrick.pordage@cmrsurgical.com/ sarah.ghabina@cmrsurgical.com
+44 (0)7864 922341 /+44 (0)7749 432373
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom